| アブストラクト | WHAT IS KNOWN AND OBJECTIVE: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. CASE SUMMARY: A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. WHAT IS NEW AND CONCLUSION: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease. |
|---|
| ジャーナル名 | Journal of clinical pharmacy and therapeutics |
|---|
| 投稿日 | 2016/5/19 |
|---|
| 投稿者 | Garcia, M; Aranburu, M A; Palacios-Zabalza, I; Lertxundi, U; Aguirre, C |
|---|
| 組織名 | Basque Country Pharmacovigilance Unit, Galdakao-Usansolo Hospital, Galdakao,;Spain.;Mutriku Primary Health Care, Mutriku, Spain.;Pharmacy Service, Galdakao-Usansolo Hospital, Galdakao, Spain.;Pharmacy Service, Araba's Mental Health Network, Vitoria-Gasteiz, Spain.;Department of Pharmacology, Faculty of Medicine, University of Basque Country,;Leioa, Spain. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/27191539/ |
|---|
